Business Context and Reporting Period
Company: Veeva Systems Inc.
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended April 30, 2026 (Fiscal Q1 2027)
Business Overview: Veeva is the leading provider of industry cloud solutions for the global life sciences industry, offering cloud software, AI, data, and business consulting. The company operates as a single reporting segment, with solutions divided into Commercial Solutions (CRM, Data Cloud) and R&D and Quality Solutions (Development Cloud, Quality Cloud).
Key Financial Metrics
| Metric | Q1 2026 (Current) | Q1 2025 (Prior Year) | Change |
|---|---|---|---|
| Total Revenues | $882.9 million | $759.0 million | +16% |
| Subscription Revenues | $730.2 million | $634.8 million | +15% |
| Professional Services & Other | $152.8 million | $124.3 million | +23% |
| Gross Profit | $662.0 million | $585.2 million | +13% |
| Gross Margin | 75.0% | 77.0% | -200 bps |
| Operating Income | $273.1 million | $233.7 million | +17% |
| Net Income | $260.9 million | $228.2 million | +14% |
| Diluted EPS | $1.57 | $1.37 | +15% |
| Operating Cash Flow | $1,127.1 million | $877.2 million | +28% |
| Cash & Short-Term Investments | $7.3 billion | $6.6 billion (approx.) | N/A |
Debt & Liquidity: The company reported no long-term debt on the balance sheet. Total current liabilities were $1.7 billion, primarily driven by deferred revenue ($1.48 billion). As of April 30, 2026, cash, cash equivalents, and short-term investments totaled $7.3 billion.
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased by $124 million (16%). Subscription revenue grew by $95 million, driven by expanding usage by existing customers and annual inflation adjustments. R&D and Quality Solutions contributed $63 million of the subscription growth, while Commercial Solutions contributed $32 million.
- Margin Compression: Gross margin decreased to 75% from 77%. The decline was primarily due to a decrease in professional services margin (20% vs. 23%) driven by headcount expansion to support demand, and increased computing infrastructure and data costs for subscription services.
- Operating Expenses: Total operating expenses rose 11% to $388.9 million. Research and Development (R&D) expenses increased 13% due to higher compensation and headcount. Sales and Marketing expenses increased 13% for similar reasons.
- Acquisition: On March 9, 2026, Veeva acquired Ostro (Rise Healthcare Tech, Inc.) for a total consideration of $90 million ($70 million net of cash). Ostro provides an AI-driven engagement platform for life sciences.
- Share Repurchases: The company repurchased 1.26 million shares for approximately $221 million during the quarter. As of April 30, 2026, $1.6 billion remained available under the $2 billion repurchase program authorized in January 2026.
Guidance, Outlook, and Risks
Management Commentary:
- Outlook: Management expects R&D and Quality Solutions to continue increasing as a percentage of total revenues. Cost of subscription and professional services is expected to increase in absolute dollars due to usage growth and continued investment in data solutions and the services organization.
- Tax Impact: The effective tax rate increased to 24.9% from 23.6%, primarily due to discrete tax deficiencies related to equity compensation. The "One Big Beautiful Bill Act" (OBBBA) is expected to reduce cash tax obligations for the remainder of the fiscal year.
- Non-GAAP Measures: Adjusted operating income was $395.4 million (Non-GAAP), excluding stock-based compensation ($119.3 million) and amortization of purchased intangibles ($3.0 million).
Key Risks & Contingencies:
- CRM Migration: The company is migrating customers from its legacy Salesforce-based CRM to its proprietary Vault CRM. This transition carries risks of disruption, customer churn, and increased costs. The legacy platform support ends December 31, 2029.
- Competition: Intense competition exists, particularly from Salesforce, which has announced commitments from some large Veeva CRM customers to switch platforms.
- Regulatory Environment: The life sciences industry is heavily regulated. Changes in drug pricing, healthcare funding, and data privacy laws (e.g., EU Data Act, GDPR) could impact demand and compliance costs.
- Third-Party Reliance: Veeva relies on Amazon Web Services and Salesforce for infrastructure. Disruptions at these providers could adversely affect operations.
Investor Verification Checklist
- CRM Migration Progress: Verify the rate of customer migration from legacy CRM to Vault CRM and any associated churn or revenue impact.
- Competitive Landscape: Monitor announcements regarding customer defections to Salesforce or other competitors, particularly in the CRM segment.
- Margin Trajectory: Assess whether the compression in professional services margins stabilizes as the expanded headcount becomes fully productive.
- Acquisition Integration: Review the integration progress and revenue contribution of the Ostro acquisition.
- Tax Rate Volatility: Monitor the impact of the OBBBA and equity compensation fluctuations on the effective tax rate and cash tax payments.
- Share Repurchase Activity: Track the pace of share repurchases under the remaining $1.6 billion authorization.